This is consistent with recent reports highlighting the critical role of DC activation in improving responses to immunotherapy and PDT.[8, 40] Thus, nanomedicine‐based PDT targeting the SOX9/TIMP1/FAK/PI3K axis provides a novel strategy for precision immunotherapy in GC. The gene discussed is PTK2; the disease is gastric cancer.